{"id":193,"date":"2020-06-03T15:47:38","date_gmt":"2020-06-03T13:47:38","guid":{"rendered":"https:\/\/semmelweis.hu\/gyermekklinika1\/?page_id=193"},"modified":"2025-06-02T10:09:16","modified_gmt":"2025-06-02T08:09:16","slug":"gasztroenterologiai-munkacsoport","status":"publish","type":"page","link":"https:\/\/semmelweis.hu\/bokayklinika\/kutatas\/gasztroenterologiai-munkacsoport\/","title":{"rendered":"Gasztroenterol\u00f3giai \u00e9s Hepatol\u00f3giai munkacsoport"},"content":{"rendered":"
Munkacsoport vezet\u0151<\/span><\/span>:<\/strong> <\/p>\n

Dr. <\/span>Dezs\u0151fi-<\/span>Gottl<\/span> Antal<\/span>,<\/span> PhD<\/span>, <\/span>habilit\u00e1lt <\/span>egyetemi docens<\/span><\/span><\/p>\n

Munkacsoport <\/span>aktu\u00e1lis <\/span>tagjai<\/span>:
\n<\/span><\/strong>Dr. Szab\u00f3 Dol\u00f3resz, PhD, egyetemi tan\u00e1rseg\u00e9d<\/span>
\n<\/span>Dr. L\u00f3th Szendile, klinika szakorvos
\n<\/span>Dr. Perneczki Andrea, klinikai szakorvos
\n<\/span>Dr. Hazay Dorottya, klinikai szakorvos<\/span><\/p>\n

Hallgat\u00f3k:
\n<\/span><\/span><\/strong>Dr. Erd\u00e9lyi-Percs \u00c9va, PhD hallgat\u00f3
\n<\/span>Dr. Mohhamad Shagrani, PhD hallgat\u00f3
\n<\/span>Balogh Andr\u00e1s<\/span>,<\/span> TDK hallgat\u00f3
\n<\/span>Tam\u00e1s Marcell, TDK hallgat\u00f3
\n<\/span>Guti Petra, TDK hallgat\u00f3
\n<\/span>Vajcs Luca, TDK hallgat\u00f3<\/span><\/p>\n<\/div>\n

Hepatol\u00f3gia<\/span> Munkacsoport<\/span><\/strong><\/p>\n

A <\/span>m\u00e1jbeteg gyermekek magasszint\u0171 gondoz\u00e1s\u00e1n t\u00fal, <\/span>elhivatottak vagyunk az <\/span>egyes k\u00f3rk\u00e9pek <\/span>patomechanizmus\u00e1nak<\/span> megismer\u00e9s\u00e9ben, illetve a kezel\u00e9s optimaliz\u00e1l\u00e1s\u00e1ban.<\/span><\/p>\n

A m\u00e1j\u00e1t\u00fcltet\u00e9sen \u00e1tesett gyermekek orsz\u00e1gos gondoz\u00f3 centrumak\u00e9nt lehet\u0151s\u00e9g\u00fcnk ny\u00edlik e betegek sz\u00e9lesk\u00f6r\u0171 k\u00f6vet\u00e9s\u00e9re. Ezek k\u00f6z\u00fcl kiemelend\u0151 a transzplant\u00e1ci\u00f3t k\u00f6vet\u0151 <\/span>immunfenot\u00edpus<\/span> \u00e9s <\/span>donorscpecifikus<\/span> antitest vizsg\u00e1lata (\u00e1raml\u00e1si <\/span>citometria<\/span>, immunhisztok\u00e9mia), melyek a transzplant\u00e1ci\u00f3 hossz\u00fat\u00e1v\u00fa kimenetel\u00e9t befoly\u00e1solhatj\u00e1k (<\/span>pl<\/span>: <\/span>graft<\/span> fibrosis<\/span>). Tov\u00e1bb\u00e1 c\u00e9lunk a m\u00e1j\u00e1t\u00fcltetett gyermekek <\/span>cardiovascul\u00e1ris<\/span> \u00e9s a metabolikus st\u00e1tusz\u00e1nak rendszeres felm\u00e9r\u00e9se, illetve a post-transzplant\u00e1ci\u00f3s metabolikus szindr\u00f3ma komplex gondoz\u00e1sa, melyhez a laborat\u00f3riumi \u00e9s <\/span>antropometriai<\/span> vizsg\u00e1latokon t\u00fal lehet\u0151s\u00e9g\u00fcnk van az aorta pulzushull\u00e1m terjed\u00e9si sebess\u00e9g\u00e9nek (PWV) m\u00e9r\u00e9s\u00e9re is. A csontanyagcsere rendszeres <\/span>monitoriz\u00e1l\u00e1s\u00e1val<\/span> (<\/span>biomarkerek<\/span>, <\/span>osteodensitometria<\/span>) kapcsolatot keres\u00fcnk az alkalmazott gy\u00f3gyszeres ter\u00e1pia \u00e9s a <\/span>graftfunkci\u00f3<\/span> csontrendszerre kifejtett hat\u00e1sa k\u00f6z\u00f6tt.<\/span><\/span><\/p>\n

Az int\u00e9zm\u00e9ny\u00fcnkben gondozott autoimmun m\u00e1jbeteg gyermekek immunol\u00f3giai karakteriz\u00e1l\u00e1sa (\u00e1raml\u00e1si <\/span>citometria<\/span>, immunhisztok\u00e9mia) lehet\u0151s\u00e9get ny\u00fajt egyes immunsejt <\/span>szubpopul\u00e1ci\u00f3k<\/span> patomechanizmusban<\/span> bet\u00f6lt\u00f6tt szerep\u00e9nek vizsg\u00e1lat\u00e1ra. Tov\u00e1bb\u00e1 kapcsolatot keres\u00fcnk az egyes jellemz\u0151 immunsejt eloszl\u00e1s \u00e9s a betegs\u00e9g lefoly\u00e1s k\u00f6z\u00f6tt, illetve ter\u00e1pi\u00e1s v\u00e1laszk\u00e9szs\u00e9g k\u00f6z\u00f6tt.<\/span><\/p>\n

Munkacsoportunk nemzetk\u00f6zi regiszterekhez csatlakozva hozz\u00e1j\u00e1rul egyes k\u00f3rk\u00e9pek <\/span>patomechanizmus\u00e1nak<\/span>, lefoly\u00e1s\u00e1nak, kezel\u00e9sre adott ter\u00e1pi\u00e1s v\u00e1lasz\u00e1nak megismer\u00e9s\u00e9hez (<\/span>biliaris<\/span> atresia<\/span>, Wilson-k\u00f3r, <\/span>Alagille<\/span>-szindr\u00f3ma, autoimmun m\u00e1jbetegs\u00e9g, <\/span>progressz\u00edv<\/span> familiaris<\/span> cholestasis<\/span>).<\/span><\/span><\/p>\n

Kutat\u00e1si t\u00e9m\u00e1k<\/span><\/span>:
\n<\/span><\/span><\/strong><\/p>\n

    \n
  • A gyermekkori autoimmun hepatitis immunol\u00f3giai karakteriz\u00e1l\u00e1sa<\/span><\/li>\n
  • A flow-cytometria autoimmun hepatitises betegek ut\u00e1nk\u00f6vet\u00e9sre val\u00f3 alkalmass\u00e1g\u00e1nak vizsg\u00e1lata<\/span><\/li>\n
  • Donor specifikus antitestek szerep\u00e9nek vizsg\u00e1lata m\u00e1jtranszplant\u00e1lt gyermekekben<\/span><\/li>\n
  • A hum\u00e1n leukocyta antig\u00e9n \u00e9s a sz\u00f6veti szint\u0171 immunsejt eloszl\u00e1s szerep\u00e9nek vizsg\u00e1lata gyermekkori autoimmun hepatitis patomechanizmus\u00e1ban \u00e9s lefoly\u00e1s\u00e1ban<\/span><\/li>\n
  • Magyar \u00e9s nemzetk\u00f6zi Wilson-k\u00f3r regiszter<\/span><\/li>\n
  • A cytomegalov\u00edrus fert\u0151z\u00e9s hat\u00e1sa a biliaris artesia kimenetel\u00e9re<\/span><\/li>\n
  • Biliaris atresia csecsem\u0151kori sz\u0171r\u0151vizsg\u00e1lat\u00e1nak m\u00f3dszertani fejleszt\u00e9se<\/span><\/li>\n
  • Fontan-kering\u00e9s asszoci\u00e1lt m\u00e1jbetegs\u00e9g (FALD) term\u00e9szetes lefoly\u00e1s\u00e1nak vizsg\u00e1lata<\/span><\/li>\n
  • Gyermekkori kezdet\u0171 sclerotisalo cholangitis term\u00e9szetes lefoly\u00e1s\u00e1nak vizsg\u00e1lata<\/span><\/li>\n<\/ul>\n

    Nemzetk\u00f6zi egy\u00fcttm\u0171k\u00f6d\u00e9sek<\/span>:<\/span><\/span><\/span><\/span><\/strong><\/p>\n

      \n
    • A velesz\u00fcletett porto-sziszt\u00e9m\u00e1s shunt\u00f6k nemzetk\u00f6zi nyilv\u00e1ntart\u00e1sa (IRCPSS registry)<\/span><\/li>\n
    • Nemzetk\u00f6zi biliaris atresia regiszter (EBAR – <\/span>ERN RARE LIVER Biliaris Atresia Registry<\/span>)<\/span><\/li>\n
    • Poszt transzplant metabolikus szindr\u00f3ma (PTMS) vizsg\u00e1lata m\u00e1j\u00e1t\u00fcltetett gyermekekben<\/span><\/li>\n
    • The Global Alagille Alliance (GALA study)<\/span><\/li>\n
    • NAtural Course and Prognosis of PFIC and Effect of Biliary Diversion (NAPPED study)<\/span><\/li>\n
    • TreatFIC study<\/span><\/li>\n<\/ul>\n

      Elm\u00falt \u00e9vek legfontosabb tudom\u00e1nyos eredm\u00e9nyei:<\/span><\/span><\/strong><\/p>\n

      Tam\u00e1s Marcell, 2023 \u2013 36. OTDK, II. d\u00edj<\/span><\/span><\/p>\n

      Elm\u00falt \u00e9vek<\/span> munkacsoporthoz<\/span> k\u00f6thet\u0151<\/span> legfontosabb publik\u00e1ci\u00f3i<\/span><\/span>:<\/span><\/span><\/strong><\/p>\n

      Lenz, <\/span>Dominic<\/span> ;<\/span> Schlieben<\/span>, Lea <\/span>D. ;<\/span> Shimura<\/span>, <\/span>Masaru<\/span> ;<\/span> Bianzano<\/span>, <\/span>Alyssa<\/span> ;<\/span> Smirnov<\/span>, <\/span>Dmitrii<\/span> ;<\/span> Kopajtich<\/span>, <\/span>Robert ;<\/span> Berutti<\/span>, <\/span>Riccardo<\/span> ;<\/span> Adam, <\/span>Ruediger<\/span> ;<\/span> Aldrian<\/span>, <\/span>Denise ;<\/span> Baric<\/span>, <\/span>Ivo<\/span> et<\/span> al<\/span>. <\/span>Genetic<\/span> landscape<\/span> of <\/span>pediatric<\/span> acute<\/span> liver<\/span> failure<\/span> of <\/span>indeterminate<\/span> origin<\/span>. HEPATOLOGY <\/span>79 :<\/span> 5 pp. 1075-<\/span>1087. ,<\/span> 13 p. (2024)<\/span><\/span><\/em><\/p>\n

      T\u00f3bi<\/span>, Luca ; <\/span>Prehoda<\/span>, Bence ; Balogh, Anna M. ; Nagyp<\/span>\u00e1<\/span>l, Petra ; Kov<\/span>\u00e1<\/span>cs, Kriszti<\/span>\u00e1<\/span>n ; <\/span>Miheller<\/span>, P<\/span>\u00e1<\/span>l ; <\/span>Ili<\/span>\u00e1<\/span>s<\/span>, <\/span>\u00c1<\/span>kos ; Dezs<\/span>\u0151<\/span>fi-<\/span>Gottl<\/span>, Antal ; Cseh, <\/span>\u00c1<\/span>ron: <\/span>Transition<\/span> is <\/span>associated<\/span> with<\/span> lower<\/span> disease<\/span> activity<\/span>, <\/span>fewer<\/span> relapses<\/span>, <\/span>better<\/span> medication<\/span> adherence<\/span>, and <\/span>lower<\/span> lost-to-follow-up<\/span> rate<\/span> as<\/span> opposed<\/span> to<\/span> self-transfer<\/span> in <\/span>pediatric-onset<\/span> inflammatory<\/span> bowel<\/span> disease<\/span> patients<\/span>: <\/span>results<\/span> of a <\/span>longitudinal<\/span>, <\/span>follow-up<\/span>, <\/span>controlled<\/span> study.THERAPEUTIC<\/span> ADVANCES IN GASTROENTEROLOGY 17 <\/span>Paper<\/span>: 17562848241252947 , 24 p. (2024)<\/span><\/span><\/em><\/p>\n

      Boros, Kriszta <\/span>Katinka ;<\/span> Veres, <\/span>G\u00e1bor ;<\/span> Cseprek\u00e1l<\/span>, <\/span>Orsolya ;<\/span> Pint\u00e9r, Hajnalka <\/span>Krisztina ;<\/span> Richter, <\/span>\u00c9va ;<\/span> Cseh, <\/span>\u00c1ron ;<\/span> Dezs\u0151fi-<\/span>Gottl<\/span>, <\/span>Antal ;<\/span> Arat\u00f3, <\/span>Andr\u00e1s ;<\/span> Reusz<\/span>, <\/span>Gy\u00f6rgy ;<\/span> Dohos, D\u00f3ra <\/span>et<\/span> al<\/span>. Body <\/span>composition<\/span>, <\/span>physical<\/span> activity<\/span>, and <\/span>quality<\/span> of life in <\/span>pediatric<\/span> patients<\/span> with<\/span> inflammatory<\/span> bowel<\/span> disease<\/span> on<\/span> anti<\/span>-TNF <\/span>therapy<\/span>\u2014an <\/span>observational<\/span> follow-up<\/span> study<\/span>. EUROPEAN JOURNAL OF CLINICAL NUTRITION <\/span>77 :<\/span> 3 pp. 380-385., 6 p. (2023)<\/span><\/span><\/em><\/p>\n

      Cser\u00e9p, <\/span>Melinda ;<\/span> Szab<\/span>\u00f3<\/span>, <\/span>Brigitta ;<\/span> T<\/span>\u00f3<\/span>th-<\/span>Heyn<\/span>, <\/span>P<\/span>\u00e9<\/span>ter ;<\/span> Luczay<\/span>, <\/span>Andrea ;<\/span> Dezs<\/span>\u0151<\/span>fi-<\/span>Gottl<\/span>, <\/span>Antal ;<\/span> Cseh, <\/span>\u00c1<\/span>ron ;<\/span> V<\/span>\u00e1<\/span>rnai, <\/span>Nikoletta ;<\/span> P<\/span>\u00e1<\/span>szthy<\/span>, <\/span>Bea ;<\/span> Szab<\/span>\u00f3<\/span>, J. <\/span>Attila ;<\/span> Szumska<\/span>, <\/span>Irena<\/span>: A kognit<\/span>\u00ed<\/span>v <\/span>\u00e9<\/span>rzelemszab<\/span>\u00e1<\/span>lyoz<\/span>\u00e1<\/span>s szerepe az ev<\/span>\u00e9<\/span>szavart<\/span>\u00fc<\/span>netekben egyes serd<\/span>\u00fc<\/span>l<\/span>\u0151<\/span>kori kr<\/span>\u00f3<\/span>nikus betegs<\/span>\u00e9<\/span>gekben. ORVOSI HETILAP <\/span>164 :<\/span> 48 pp. 1895-<\/span>1903. ,<\/span> 9 p. (2023)<\/span><\/em><\/p>\n

      Felzen, <\/span>A. ;<\/span> van, <\/span>Wessel<\/span> D.B.E. ;<\/span> Gonzales<\/span>, <\/span>E. ;<\/span> Thompson, <\/span>R.J. ;<\/span> Jankowska<\/span>, <\/span>I. ;<\/span> Shneider<\/span>, <\/span>B.L. ;<\/span> Sokal<\/span>, <\/span>E. ;<\/span> Grammatikopoulos<\/span>, <\/span>T. ;<\/span> Kadaristiana<\/span>, <\/span>A. ;<\/span> Jacquemin<\/span>, E. <\/span>et<\/span> al<\/span>. <\/span>Genotype-phenotype<\/span> relationships<\/span> of <\/span>truncating<\/span> mutations<\/span>, p.E297G and p.D482G in <\/span>bile<\/span> salt<\/span> export <\/span>pump<\/span> deficiency<\/span>. JHEP <\/span>Reports<\/span> 5 :<\/span> 2 <\/span>Paper<\/span>: <\/span>100626 ,<\/span> 11 p. (2023)<\/span><\/span><\/em><\/p>\n

      Molnar<\/span>, Maria <\/span>Judit ;<\/span> Szlepak<\/span>, <\/span>Tamas<\/span> ;<\/span> Cs<\/span>\u00fc<\/span>rke<\/span>, <\/span>Ildik<\/span>\u00f3<\/span> ;<\/span> Loth<\/span>, <\/span>Szendile<\/span> ;<\/span> K<\/span>\u00e1<\/span>poszta, <\/span>Rita ;<\/span> Erd<\/span>\u0151<\/span>s, <\/span>Melinda ;<\/span> Dezs<\/span>\u0151<\/span>fi, Antal: <\/span>Case<\/span> report<\/span>: The <\/span>spectrum<\/span> of SMPD1 <\/span>pathogenic<\/span> variants<\/span> in Hungary. FRONTIERS IN GENETICS 14 <\/span>Paper<\/span>: <\/span>1158108 ,<\/span> 6 p. (2023)<\/span><\/span><\/em><\/p>\n

      Vandriel<\/span>, Shannon <\/span>M. ;<\/span> Li, Li-<\/span>Ting<\/span> ;<\/span> She<\/span>, <\/span>Huiyu<\/span> ;<\/span> Wang<\/span>, <\/span>Jian-<\/span>She<\/span> ;<\/span> Gilbert, Melissa <\/span>A. ;<\/span> Jankowska<\/span>, <\/span>Irena<\/span> ;<\/span> Czubkowski<\/span>, <\/span>Piotr<\/span> ;<\/span> Gliwicz-Miedzinska<\/span>, <\/span>Dorota<\/span> ;<\/span> Gonzales<\/span>, Emmanuel <\/span>M. ;<\/span> Jacquemin<\/span>, Emmanuel <\/span>et<\/span> al<\/span>. <\/span>Natural<\/span> history<\/span> of <\/span>liver<\/span> disease<\/span> in a <\/span>large<\/span> international<\/span> cohort<\/span> of <\/span>children<\/span> with<\/span> Alagille<\/span> syndrome<\/span>: <\/span>Results<\/span> from<\/span> the<\/span> GALA <\/span>study<\/span>. HEPATOLOGY <\/span>77 :<\/span> 2 pp. 512-<\/span>529. ,<\/span> 17 p. (2023)<\/span><\/span><\/em><\/p>\n

      *****<\/span><\/span><\/strong><\/p>\n

      Munkacsoport vezet\u0151<\/span><\/span>:<\/strong> <\/p>\n

      Dr. Cseh \u00c1ron, PhD, egyetemi <\/span>adjunktus<\/span><\/span><\/p>\n

      Munkacsoport <\/span>aktu\u00e1lis <\/span>tagjai<\/span>:
      \n<\/span><\/strong>Prof. Dr. Arat\u00f3 Andr\u00e1s, egyetemi tan\u00e1r, az MTA doktora
      \n<\/span>Dr. B\u00e9res N\u00f3ra, PhD, egyetemi tan\u00e1rseg\u00e9d
      \n<\/span>Dr. Prehoda Bence, klinika szakorvos, PhD hallgat\u00f3
      \n<\/span>Dr. T\u00e9l B\u00e1lint, PhD, szakorvosjel\u00f6lt
      \n<\/span>Dr. Boros Kriszta Katinka, PhD, szakorvosjel\u00f6lt<\/span><\/p>\n

      Hallgat\u00f3k:
      \n<\/span><\/span><\/strong>Dr. T\u00f3bi Luca, PhD hallgat\u00f3
      \n<\/span>Dr. Nagyp\u00e1l Petra, PhD hallgat\u00f3
      \n<\/span>Dr. Balogh Anna, PhD hallgat\u00f3
      \n<\/span>Dr. Kov\u00e1cs Kriszti\u00e1n, PhD hallgat\u00f3
      \n<\/span>Horv\u00e1th Fanni, MD\/PhD hallgat\u00f3
      \n<\/span>Vajda M\u00e1t\u00e9, TDK hallgat\u00f3
      \n<\/span>Mezei D\u00f3ra, TDK hallgat\u00f3
      \n<\/span>Lempeg Zs\u00f3fia, TDK hallgat\u00f3
      \n<\/span>Horv\u00e1t Fanni, TDK hallgat\u00f3
      \n<\/span>Boros Emma, TDK hallgat\u00f3
      \n<\/span>Katona Eszter, TDK hallgat\u00f3
      \n<\/span>Nagy \u00c1d\u00e1m, TDK hallgat\u00f3
      \n<\/span>Pancza Zs\u00f3fia, TDK hallgat\u00f3<\/span><\/p>\n<\/div>\n

      Gasztroenterol\u00f3giai<\/span> Munkacsoport<\/span><\/span><\/strong><\/span><\/p>\n

      A <\/span>gas<\/span>z<\/span>troenterol\u00f3giai<\/span> kutat\u00e1sok f\u0151 ir\u00e1nya a <\/span>gyullad\u00e1sos<\/span> b\u00e9lbetegs\u00e9gekben (IBD<\/span> –<\/span> Crohn<\/span> betegs\u00e9g<\/span> \u00e9s<\/span> c<\/span>olitis<\/span> ulcer<\/span>os<\/span>a<\/span>) szenved\u0151 gyermekek \u00e9letmin\u0151s\u00e9g\u00e9nek a jav\u00edt\u00e1s\u00e1t szolg\u00e1lja. A <\/span>gyullad\u00e1sos<\/span> b\u00e9lbetegs\u00e9g <\/span>etiol\u00f3gi\u00e1ja<\/span> a mai napig nem tiszt\u00e1zott. Felmer\u00fcl immunol\u00f3giai-, k\u00f6rnyezeti- \u00e9s genetikai t\u00e9nyez\u0151k, valamint a <\/span>mikrobiom<\/span> megv\u00e1ltoz\u00e1sa is. Ez\u00e9rt <\/span>t\u00f6bbek k\u00f6z\u00f6tt <\/span>vizsg\u00e1ljuk <\/span>a <\/span>gyullad\u00e1sos<\/span> b\u00e9lbetegekben l\u00e9trej\u00f6v\u0151 <\/span>mikrobiom<\/span>– \u00e9s <\/span>metabolom<\/span> v\u00e1ltoz\u00e1sokat, valamint ezek \u00f6sszef\u00fcgg\u00e9s\u00e9t a betegs\u00e9g aktivit\u00e1s\u00e1val \u00e9s ter\u00e1pi\u00e1s v\u00e1laszk\u00e9szs\u00e9g\u00e9vel. Tov\u00e1bb\u00e1 keress\u00fck az esetleges j\u00f6v\u0151beni <\/span>biomarkereket<\/span> a <\/span>gyullad\u00e1sos<\/span> b\u00e9lbetegs\u00e9g mihamarabbi diagnosztiz\u00e1l\u00e1s\u00e1hoz, \u00e9s a ter\u00e1pia k\u00f6nnyebb k\u00f6vet\u00e9s\u00e9hez. Bevezet\u00e9sre ker\u00fclt a betegs\u00e9g legkorszer\u0171bb kezel\u00e9si form\u00e1it jelent\u0151 biol\u00f3giai ter\u00e1pi\u00e1k gy\u00f3gyszer- \u00e9s ellenanyagszintm\u00e9r\u00e9se, ami a kezdeti kutat\u00e1si f\u00e1zisb\u00f3l m\u00e1r hazai szinten is a klinikai gyakorlatban sz\u00e9les k\u00f6rben elterjedt. Vizsg\u00e1ljuk a proakt\u00edv \u00e9s a reakt\u00edv gy\u00f3gyszerszintm\u00e9r\u00e9s k\u00f6z\u00f6tti \u00e9letmin\u0151s\u00e9get befoly\u00e1sol\u00f3 elt\u00e9r\u00e9seket, hossz\u00fat\u00e1v\u00fa ter\u00e1pi\u00e1s hasznukat. Tov\u00e1bb\u00e1 vizsg\u00e1ljuk <\/span>gyullad\u00e1sos<\/span> b\u00e9lbetegs\u00e9gben az <\/span>eosinophil<\/span> granulocyt\u00e1k<\/span> szerep\u00e9t is. <\/span>A <\/span>gyullad\u00e1sos<\/span> b\u00e9lbetegek \u00e9letmin\u0151s\u00e9g\u00e9nek jav\u00edt\u00e1s\u00e1<\/span>na<\/span>k <\/span>\u00e9rdek\u00e9ben<\/span> c\u00e9lul t\u0171zt\u00fck ki, hogy struktur\u00e1ltan, a nemzetk\u00f6zi aj\u00e1nl\u00e1soknak megfelel\u0151en <\/span>tranz\u00edcion\u00e1ljuk<\/span> a feln\u0151ttkort el\u00e9rt betegeket, \u00e9s vizsg\u00e1ljuk ennek hasznoss\u00e1g\u00e1t a betegs\u00e9g r\u00f6vid- \u00e9s hossz\u00fat\u00e1v\u00fa kimenetel\u00e9re is.<\/span> A <\/span>gyullad\u00e1sos<\/span> b\u00e9lbetegs\u00e9g<\/span>ben fokozott a <\/span>hegesed\u0151 epe\u00fati gyullad\u00e1s, a <\/span>sclerotisalo<\/span> cholangitis<\/span> (SC)<\/span> el\u0151fordul\u00e1s\u00e1nak kock\u00e1zata<\/span>. <\/span>Egyik \u00faj<\/span> kutat\u00e1si ir\u00e1ny<\/span>unk<\/span> az <\/span>SC-IBD-s betegek <\/span>term\u00e9szetes betegs\u00e9glefoly\u00e1s\u00e1nak, valamint <\/span>prognosztikai t\u00e9nyez\u0151inek vizsg\u00e1lata<\/span>.<\/span><\/p>\n

      A Patol\u00f3giai, Igazs\u00e1g\u00fcgyi \u00e9s Biztos\u00edt\u00e1si Orvostani Int\u00e9zet k\u00f6zrem\u0171k\u00f6d\u00e9s\u00e9vel egy mesters\u00e9ges intelligencia \u00e1ltal vez\u00e9relt programot fejleszt\u00fcnk, amelynek seg\u00edts\u00e9g\u00e9vel meghat\u00e1rozzuk az <\/span>eosinophil<\/span> granulocyt\u00e1k<\/span> mennyis\u00e9g\u00e9t <\/span>b\u00e9lbiopszi\u00e1kban<\/span>. A vizsg\u00e1lat c\u00e9lja meghat\u00e1rozni, hogy a betegs\u00e9g kezdete befoly\u00e1solja-e az <\/span>eosinophilek<\/span> mennyis\u00e9g\u00e9t f\u0151leg korai kezdet\u0171 <\/span>gyullad\u00e1sos<\/span> b\u00e9lbetegs\u00e9gben, \u00e9s hogy l\u00e1that\u00f3-e az <\/span>eosinophil<\/span> sejtsz\u00e1m \u00e9s a betegs\u00e9g progn\u00f3zisa k\u00f6z\u00f6tt kapcsolat.<\/span><\/span><\/p>\n

      Ezek mellett vizsg\u00e1ljuk a b\u00e9lhez k\u00f6t\u00f6tt <\/span>mucos\u00e1lis<\/span> immunrendszer elt\u00e9r\u00e9seit <\/span>immunmedi\u00e1lt<\/span> b\u00e9lbetegs\u00e9gekben. Vizsg\u00e1lataink <\/span>gyullad\u00e1sos<\/span> b\u00e9lbetegs\u00e9gekre, <\/span><\/span>liszt\u00e9rz\u00e9kenys\u00e9gre<\/span> (<\/span>c\u00f6li\u00e1kia<\/span>) \u00e9s az allergi\u00e1s <\/span>gastroenterol\u00f3giai<\/span> k\u00f3rk\u00e9pekre ir\u00e1nyulnak. Ezekben a k\u00f3rk\u00e9pekben a <\/span>gyullad\u00e1sos<\/span> folyamat kialakul\u00e1s\u00e1t tanulm\u00e1nyozzuk, de arra is keress\u00fck a v\u00e1laszt, hogy <\/span>gyullad\u00e1sos<\/span> b\u00e9lbetegs\u00e9gben hogyan j\u00f6n l\u00e9tre a sz\u0171k\u00fcleteket okoz\u00f3 hegesed\u00e9s (<\/span>fibr\u00f3zis<\/span>). Keress\u00fck azokat a klinikai \u00e9s laborat\u00f3riumi jeleket is, amelyek seg\u00edtenek ezeknek a k\u00f3rk\u00e9peknek a pontosabb diagnosztik\u00e1j\u00e1ban.<\/span><\/span><\/p>\n

      Kutat\u00e1si t\u00e9m\u00e1k<\/span><\/span>:<\/span><\/span><\/strong><\/p>\n

        \n
      • A korai kezdet\u0171 gyullad\u00e1sos b\u00e9lbetegs\u00e9g saj\u00e1toss\u00e1gai \u00e9s kezel\u00e9se<\/span><\/li>\n
      • A perif\u00e9ri\u00e1s \u00e9s sz\u00f6veti eozinof\u00edlia jelent\u0151s\u00e9ge gyermekkori gyullad\u00e1sos b\u00e9lbetegs\u00e9gben<\/span><\/li>\n
      • A t\u00e1pl\u00e1lkoz\u00e1s szerepe gyermekkori Crohn betegs\u00e9g kialakul\u00e1s\u00e1ban \u00e9s kezel\u00e9s\u00e9ben<\/span><\/li>\n
      • Biomarker vizsg\u00e1latok gyermekkori gyullad\u00e1sos b\u00e9lbetegs\u00e9gben<\/span><\/li>\n
      • Mikrobiom \u00e9s metabolom vizsg\u00e1latok gyermekkori gyullad\u00e1sos b\u00e9lbetegs\u00e9gben, ter\u00e1pi\u00e1s lehet\u0151s\u00e9gek<\/span>\u00a0<\/span><\/li>\n
      • Biol\u00f3giai ter\u00e1pi\u00e1k optimaliz\u00e1l\u00e1sa gy\u00f3gyszer- \u00e9s antitestszint m\u00e9r\u00e9ssel gyermekkori gyullad\u00e1sos b\u00e9lbetegs\u00e9gben<\/span><\/li>\n
      • A c\u00f6li\u00e1ki\u00e1s beteg gyermekek \u00e9letmin\u0151s\u00e9g\u00e9nek jav\u00edt\u00e1sa<\/span><\/li>\n
      • A tranz\u00edci\u00f3 \u00e9s mentor\u00e1l\u00e1s szerepe a gyullad\u00e1sos b\u00e9lbeteg gyermekek kezel\u00e9s\u00e9ben<\/span><\/li>\n
      • Prognosztikai t\u00e9nyez\u0151k vizsg\u00e1lata gyermekkori gyullad\u00e1sos b\u00e9lbetegs\u00e9gekben<\/span><\/li>\n
      • A COVID\/Long-COVID gasztrointesztin\u00e1lis hat\u00e1sai<\/span><\/li>\n
      • Gyullad\u00e1sos b\u00e9lbetegs\u00e9ggel gondozott betegek korszer\u0171 seb\u00e9szeti kezel\u00e9se<\/span><\/li>\n
      • Hirschsprung asszoci\u00e1lt gyullad\u00e1sos b\u00e9lbetegs\u00e9g<\/span><\/li>\n
      • Velesz\u00fcletett anyagcsere betegs\u00e9gek gasztroenterol\u00f3giai vonatkoz\u00e1sai<\/span><\/li>\n
      • A prec\u00edzi\u00f3s medicina lehet\u0151s\u00e9gei a gyermekkori gasztroenterol\u00f3giai \u00e9s hepatol\u00f3giai k\u00f3rk\u00e9pekben (PreMePIBD)<\/span><\/li>\n<\/ul>\n

        Nemzetk\u00f6zi egy\u00fcttm\u0171k\u00f6d\u00e9sek:<\/span><\/span><\/strong><\/p>\n

          \n
        • Pioneering Population-Scale Organoid-Based Research for Innovation and Translation in Inflammatory Bowel Disease (ORBIT-IBD study)<\/span><\/li>\n
        • CNTO1275PUC3001 A Phase 3 Study of the Efficacy, Safety and Pharmacokinetics of<\/span> Ustekinumab as Open-label Intravenous Induction Treatment Followed by Randomized Double-blind Subcutaneous Ustekinumab Maintenance in Pediatric Participants with Moderately to Severely Active Ulcerative Colitis<\/span><\/li>\n
        • CNTO1275CRD3004 A Phase 3 Study of the Efficacy, Safety, and Pharmacokinetics of Ustekinumab as Open-label Intravenous Induction Treatment Followed by Randomized Double-blind Subcutaneous Ustekinumab Maintenance in Pediatric Participants with Moderately to Severely Active Crohn\u2019s Disease<\/span><\/li>\n
        • MLN0002-3024 A Randomized, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of Vedolizumab Intravenous as Maintenance Therapy in Pediatric Subjects with Moderately to Severely Active Ulcerative Colitis Who Achieved Clinical Response Following Open-Label Vedolizumab Intravenous Therapy<\/span><\/li>\n
        • MLN0002-3025 A Randomized, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of Vedolizumab Intravenous as Maintenance Therapy in Pediatric Subjects with Moderately to Severely Active Crohn\u2019s Disease Who Achieved Clinical Response Following Open-Label Vedolizumab Intravenous Therapy<\/span><\/li>\n<\/ul>\n

          Elm\u00falt \u00e9vek legfontosabb tudom\u00e1nyos eredm\u00e9nyei:<\/span><\/span><\/strong><\/p>\n

          Urkon<\/span> Krisztina,<\/span> 2024<\/span> Marosv\u00e1s\u00e1rhelyi TDK konferenci<\/span>a<\/span>, <\/span>II. helyezett<\/span><\/p>\n

          Elm\u00falt \u00e9vek<\/span> munkacsoporthoz<\/span> k\u00f6thet\u0151<\/span> legfontosabb publik\u00e1ci\u00f3i<\/span><\/span>:<\/span><\/span><\/strong><\/p>\n

          Dennison<\/span>, Thomas <\/span>W. ;<\/span> Edgar, Rachel D.<\/span>* ;<\/span> Payne<\/span>, Felicity<\/span>* ;<\/span> Nayak<\/span>, <\/span>Komal<\/span> M. ;<\/span> Ross, Alexander D. <\/span>B. ;<\/span> Cenier<\/span>, <\/span>Aurelie<\/span> ;<\/span> Glemas<\/span>, <\/span>Claire ;<\/span> Giachero<\/span>, <\/span>Federica<\/span> ;<\/span> Foster, <\/span>April<\/span> R. ;<\/span> Tel, <\/span>Balint<\/span> ;<\/span> Harris, Rebecca<\/span>;<\/span> et<\/span> al<\/span>.<\/span> Patient-derived<\/span> organoid<\/span> biobank<\/span> identifies<\/span> epigenetic<\/span> dysregulation<\/span> of <\/span>intestinal<\/span> epithelial<\/span> MHC-I <\/span>as<\/span> a <\/span>novel<\/span> mechanism<\/span> in <\/span>severe<\/span> Crohn’s<\/span> Disease<\/span> GUT <\/span>73 :<\/span> 9 pp. 1464-<\/span>1477. ,<\/span> 14 p. (2024)<\/span><\/span><\/em><\/p>\n

          T\u00f3bi<\/span>, <\/span>Luca ;<\/span> Prehoda<\/span>, <\/span>Bence ;<\/span> Balogh, Anna <\/span>M. ;<\/span> Nagyp\u00e1l, <\/span>Petra ;<\/span> Kov\u00e1cs, <\/span>Kriszti\u00e1n ;<\/span> Miheller<\/span>, <\/span>P\u00e1l ;<\/span> Ili\u00e1s<\/span>, <\/span>\u00c1kos ;<\/span> Dezs\u0151fi-<\/span>Gottl<\/span>, <\/span>Antal ;<\/span> Cseh, \u00c1ron<\/span>. <\/span>Transition<\/span> is <\/span>associated<\/span> with<\/span> lower<\/span> disease<\/span> activity<\/span>, <\/span>fewer<\/span> relapses<\/span>, <\/span>better<\/span> medication<\/span> adherence<\/span>, and <\/span>lower<\/span> lost-to-follow-up<\/span> rate<\/span> as<\/span> opposed<\/span> to<\/span> self-transfer<\/span> in <\/span>pediatric-onset<\/span> inflammatory<\/span> bowel<\/span> disease<\/span> patients<\/span>: <\/span>results<\/span> of a <\/span>longitudinal<\/span>, <\/span>follow-up<\/span>, <\/span>controlled<\/span> study<\/span> THERAPEUTIC ADVANCES IN GASTROENTEROLOGY 17 <\/span>Paper<\/span>: <\/span>17562848241252947 ,<\/span> 24 p. (2024)<\/span><\/span><\/em><\/p>\n

          Gerasimidis<\/span>, <\/span>Konstantinos<\/span> <\/span>\u2709<\/span><\/span> ;<\/span> Russell, Richard <\/span>K. ;<\/span> Giachero<\/span>, <\/span>Federica<\/span> ;<\/span> Gkikas<\/span>, <\/span>Konstantinos<\/span> ;<\/span> Tel, <\/span>Balint ;<\/span> Assa<\/span>, <\/span>Amit ;<\/span> Bronsky<\/span>, <\/span>Jiri<\/span> ;<\/span> de <\/span>Ridder<\/span>, <\/span>Lissy<\/span> ;<\/span> Hojsak<\/span>, <\/span>Iva<\/span> ;<\/span> Jenke, Andreas <\/span>et<\/span> al<\/span>.<\/span> Precision<\/span> nutrition<\/span> in <\/span>pediatric<\/span> IBD: A <\/span>position<\/span> paper<\/span> from<\/span> the<\/span> ESPGHAN <\/span>special<\/span> interest <\/span>group<\/span> for<\/span> basic<\/span> science<\/span> and <\/span>translational<\/span> research<\/span>, <\/span>the<\/span> IBD Porto <\/span>group<\/span>, and <\/span>allied<\/span> health<\/span> professionals<\/span> JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION <\/span>78 :<\/span> 2 pp. 428-<\/span>445. ,<\/span> 18 p. (2023)<\/span><\/span><\/em><\/p>\n

          Boros, Kriszta <\/span>Katinka ;<\/span> Veres, <\/span>G\u00e1bor ;<\/span> Cseprek\u00e1l<\/span>, <\/span>Orsolya ;<\/span> Pint\u00e9r, Hajnalka <\/span>Krisztina ;<\/span> Richter, <\/span>\u00c9va ;<\/span> Cseh, <\/span>\u00c1ron ;<\/span> Dezs\u0151fi-<\/span>Gottl<\/span>, <\/span>Antal ;<\/span> Arat\u00f3, <\/span>Andr\u00e1s ;<\/span> Reusz<\/span>, <\/span>Gy\u00f6rgy ;<\/span> Dohos, D\u00f3ra <\/span>et<\/span> al<\/span>.<\/span> Body <\/span>composition<\/span>, <\/span>physical<\/span> activity<\/span>, and <\/span>quality<\/span> of life in <\/span>pediatric<\/span> patients<\/span> with<\/span> inflammatory<\/span> bowel<\/span> disease<\/span> on<\/span> anti<\/span>-TNF <\/span>therapy<\/span>\u2014an <\/span>observational<\/span> follow-up<\/span> study<\/span>. <\/span>EUROPEAN JOURNAL OF CLINICAL NUTRITION <\/span>77 :<\/span> 3 pp. 380-<\/span>385. ,<\/span> 6 p. (2023)<\/span><\/span><\/em><\/p>\n

          Kadenczki<\/span>, <\/span>Orsolya ;<\/span> Dezsofi<\/span>, <\/span>Antal ;<\/span> Cseh, <\/span>Aron<\/span> ;<\/span> Szucs<\/span>, <\/span>Daniel ;<\/span> Vass, <\/span>Noemi<\/span> ;<\/span> Nemes, <\/span>Eva ;<\/span> Tarnok<\/span>, <\/span>Andras<\/span> ;<\/span> Szakos, <\/span>Erzsebet<\/span> ;<\/span> Guthy<\/span>, <\/span>Ildiko<\/span> ;<\/span> Kovacs<\/span>, Marta <\/span>et<\/span> al<\/span>.<\/span> Disease<\/span> Activity<\/span> Is <\/span>Associated<\/span> with<\/span> Obesity<\/span> in <\/span>Newly<\/span> Diagnosed<\/span> Pediatric<\/span> Patients<\/span> with<\/span> Ulcerative<\/span> Colitis<\/span>. <\/span>INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH <\/span>19 :<\/span> 23 <\/span>Paper<\/span>: <\/span>16091 ,<\/span> 12 p. (2022)<\/span><\/span><\/em><\/p>\n

          Lippai, <\/span>Rita ;<\/span> Veres\u2011Sz\u00e9kely, <\/span>Apor ;<\/span> Sziksz<\/span>, <\/span>Erna ;<\/span> Iwakura<\/span>, <\/span>Yoichiro<\/span> ;<\/span> Pap, <\/span>Domonkos ;<\/span> Rokonay<\/span>, <\/span>R\u00e9ka ;<\/span> Szebeni, <\/span>Be\u00e1ta ;<\/span> Lotz, <\/span>G\u00e1bor ;<\/span> B\u00e9res, N\u00f3ra <\/span>J. ;<\/span> Cseh, \u00c1ron <\/span>et<\/span> al<\/span>.<\/span> Immunomodulatory<\/span> role<\/span> of <\/span>Parkinson\u2019s<\/span> disease<\/span> 7 in <\/span>inflammatory<\/span> bowel<\/span> disease<\/span>. <\/span>SCIENTIFIC REPORTS <\/span>11 :<\/span> 1 <\/span>Paper<\/span>: <\/span>14582 ,<\/span> 14 p. (2021)<\/span><\/span><\/em><\/p>\n

          T\u00e9l, <\/span>B\u00e1lint ;<\/span> Stubnya<\/span>, <\/span>Bence ;<\/span> Gede, <\/span>No\u00e9mi ;<\/span> Varj\u00fa, <\/span>P\u00e9ter ;<\/span> Kiss, <\/span>Zolt\u00e1n ;<\/span> M\u00e1rta, <\/span>Katalin ;<\/span> Hegyi, P\u00e9ter <\/span>Jen\u0151 ;<\/span> Garami, <\/span>Andr\u00e1s ;<\/span> Hegyi, <\/span>Eszter ;<\/span> Szak\u00e1cs, Zsolt <\/span>et<\/span> al<\/span>.<\/span> Inflammatory<\/span> Bowel<\/span> Diseases<\/span> Elevate<\/span> the<\/span> Risk<\/span> of <\/span>Developing<\/span> Acute<\/span> Pancreatitis<\/span>: A <\/span>Meta-analysis<\/span>. <\/span>PANCREAS <\/span>49 :<\/span> 9 pp. 1174-<\/span>1181. ,<\/span> 8 p. (2020)<\/span><\/span><\/em><\/p>\n

          B\u00e9res, N\u00f3ra <\/span>Judit ;<\/span> Szigetv\u00e1ri, <\/span>Zs\u00f3fia ;<\/span> Arat\u00f3, <\/span>Andr\u00e1s ;<\/span> Cseh, <\/span>\u00c1ron ;<\/span> M\u00fcller, Katalin <\/span>Eszter ;<\/span> Dezs\u0151fi, <\/span>Antal ;<\/span> Veres, G\u00e1bor. A gyermekkori <\/span>Crohn<\/span>-betegs\u00e9g prognosztikai t\u00e9nyez\u0151inek vizsg\u00e1lata. GYERMEKGY\u00d3GY\u00c1SZAT <\/span>71 :<\/span> 4 pp. 230-<\/span>235. ,<\/span> 6 p. (2020)<\/span><\/em><\/p>\n

          \n

          —————————— ENGLISH ——————————<\/p>\n

          In <\/span>addition<\/span> to<\/span> high-level<\/span> care<\/span> for<\/span> children<\/span> with<\/span> liver<\/span> disease<\/span>, <\/span>the<\/span> <\/span>Hepatology<\/span> Working<\/span> Group<\/span><\/span><\/strong> is <\/span>dedicated<\/span> to<\/span> understanding<\/span> the<\/span> pathomechanism<\/span> of <\/span>certain<\/span> diseases<\/span> and <\/span>optimizing<\/span> treatment<\/span>.<\/span><\/span><\/p>\n

          As<\/span> a <\/span>national<\/span> care<\/span> center <\/span>for<\/span> children<\/span> who<\/span> have<\/span> undergone<\/span> a <\/span>liver<\/span> transplant<\/span>, <\/span>we<\/span> have<\/span> the<\/span> opportunity<\/span> to<\/span> follow<\/span> up<\/span> these<\/span> patients<\/span> extensively<\/span>. Of <\/span>these<\/span>, <\/span>the<\/span> post-<\/span>transplant<\/span> immunophenotype<\/span> and donor-<\/span>specific<\/span> antibody<\/span> testing (flow <\/span>cytometry<\/span>, <\/span>immunohistochemistry<\/span>) <\/span>should<\/span> be <\/span>highlighted<\/span>, <\/span>which<\/span> can<\/span> influence<\/span> the<\/span> long-term<\/span> outcome<\/span> of <\/span>the<\/span> transplant<\/span> (<\/span>eg<\/span>: <\/span>graft<\/span> fibrosis<\/span>). <\/span>Furthermore<\/span>, <\/span>we<\/span> aim<\/span> to<\/span> regularly<\/span> assess<\/span> the<\/span> cardiovascular<\/span> and <\/span>metabolic<\/span> status of <\/span>liver<\/span> transplant<\/span> children<\/span>, <\/span>as<\/span> well<\/span> as<\/span> the<\/span> complex<\/span> care<\/span> of post-<\/span>transplantation<\/span> metabolic<\/span> syndrome<\/span>, <\/span>for<\/span> which<\/span>, in <\/span>addition<\/span> to<\/span> laboratory<\/span> and <\/span>anthropometric<\/span> tests<\/span>, <\/span>we<\/span> also<\/span> have<\/span> the<\/span> option<\/span> of <\/span>measuring<\/span> the<\/span> aortic<\/span> pulse<\/span> wave<\/span> propagation<\/span> velocity<\/span> (PWV). <\/span>By<\/span> regular<\/span> monitoring of <\/span>bone<\/span> metabolism<\/span> (<\/span>biomarkers<\/span>, <\/span>osteodensitometry<\/span>), <\/span>we<\/span> look<\/span> for<\/span> a <\/span>connection<\/span> between<\/span> the<\/span> applied<\/span> drug<\/span> therapy<\/span> and <\/span>the<\/span> effect<\/span> of <\/span>the<\/span> graft<\/span> function<\/span> on<\/span> the<\/span> bone<\/span> system<\/span>.<\/span><\/span><\/p>\n

          The <\/span>immunological<\/span> characterization<\/span> (flow <\/span>cytometry<\/span>, <\/span>immunohistochemistry<\/span>) of <\/span>children<\/span> with<\/span> autoimmune<\/span> liver<\/span> disease<\/span> cared<\/span> for<\/span> in <\/span>our<\/span> institution<\/span> provides<\/span> an <\/span>opportunity<\/span> to<\/span> investigate<\/span> the<\/span> role<\/span> of <\/span>certain<\/span> immune<\/span> cell<\/span> subpopulations<\/span> in <\/span>the<\/span> pathomechanism<\/span>. <\/span>Furthermore<\/span>, <\/span>we<\/span> are<\/span> looking<\/span> for<\/span> a <\/span>relationship<\/span> between<\/span> the<\/span> individual<\/span> characteristic<\/span> immune<\/span> cell<\/span> distribution<\/span> and <\/span>the<\/span> course<\/span> of <\/span>the<\/span> disease<\/span>, <\/span>as<\/span> well<\/span> as<\/span> between<\/span> therapeutic<\/span> responsiveness<\/span>. <\/span>By<\/span> joining<\/span> international<\/span> registries<\/span>, <\/span>our<\/span> working<\/span> group<\/span> contributes<\/span> to<\/span> understanding<\/span> the<\/span> pathomechanism<\/span>, <\/span>course<\/span>, and <\/span>therapeutic<\/span> response<\/span> of <\/span>certain<\/span> diseases<\/span> (<\/span>biliary<\/span> atresia<\/span>, <\/span>Wilson\u2019s<\/span> disease<\/span>, <\/span>Alagille<\/span> syndrome<\/span>, <\/span>autoimmune<\/span> liver<\/span> disease<\/span>, <\/span>progressive<\/span> familial<\/span> cholestasis<\/span>).<\/span><\/span><\/p>\n

          ****<\/span><\/span><\/strong><\/p>\n

          The main <\/span>direction<\/span> of <\/span>research<\/span> of <\/span>the<\/span> <\/span>G<\/span>astroenterolog<\/span>y<\/span> Working<\/span> Group<\/span><\/span><\/strong> is <\/span>to<\/span> improve<\/span> the<\/span> quality<\/span> of life of <\/span>children<\/span> suffering<\/span> from<\/span> inflammatory<\/span> bowel<\/span> diseases<\/span> (IBD, <\/span>Crohn\u2019s<\/span> disease<\/span>, <\/span>ulcerative<\/span> colitis<\/span>). The <\/span>etiology<\/span> of <\/span>inflammatory<\/span> bowel<\/span> disease<\/span> is <\/span>still<\/span> unclear<\/span>. <\/span>Immunological<\/span>, <\/span>environmental<\/span> and <\/span>genetic<\/span> factors<\/span>, <\/span>as<\/span> well<\/span> as<\/span> changes<\/span> in <\/span>the<\/span> microbiome<\/span>, <\/span>also<\/span> arise<\/span>. <\/span>Therefore<\/span>, <\/span>as<\/span> basic<\/span> research<\/span>, <\/span>we<\/span> examine<\/span> the<\/span> microbiome<\/span> and <\/span>metabolome<\/span> changes<\/span> that<\/span> occur<\/span> in <\/span>inflammatory<\/span> bowel<\/span> patients<\/span>, <\/span>as<\/span> well<\/span> as<\/span> their<\/span> correlation<\/span> with<\/span> disease<\/span> activity<\/span> and <\/span>therapeutic<\/span> responsiveness<\/span>. <\/span>Furthermore<\/span>, <\/span>we<\/span> are<\/span> looking<\/span> for<\/span> possible<\/span> future<\/span> biomarkers<\/span> for<\/span> diagnosing<\/span> inflammatory<\/span> bowel<\/span> disease<\/span> as<\/span> soon<\/span> as<\/span> possible<\/span> and <\/span>for<\/span> easier<\/span> follow-up<\/span> of <\/span>therapy<\/span>. The <\/span>measurement<\/span> of <\/span>drug<\/span> and <\/span>antibody<\/span> levels<\/span> of <\/span>biological<\/span> therapies<\/span>, <\/span>which<\/span> represent<\/span> the<\/span> most modern <\/span>forms<\/span> of <\/span>treatment<\/span> of <\/span>the<\/span> disease<\/span>, <\/span>was<\/span> introduced<\/span>, <\/span>which<\/span> was<\/span> already<\/span> widespread<\/span> in <\/span>clinical<\/span> practice<\/span> at<\/span> the<\/span> domestic<\/span> level<\/span> from<\/span> the<\/span> initial<\/span> research<\/span> phase<\/span>. <\/span>We<\/span> examine<\/span> the<\/span> differences<\/span> affecting<\/span> the<\/span> quality<\/span> of life <\/span>between<\/span> proactive<\/span> and <\/span>reactive<\/span> drug<\/span> level<\/span> measurement<\/span> and <\/span>their<\/span> long-term<\/span> therapeutic<\/span> benefits<\/span>.<\/span> In <\/span>order<\/span> to<\/span> improve<\/span> the<\/span> quality<\/span> of life of <\/span>inflammatory<\/span> bowel<\/span> patients<\/span>, <\/span>we<\/span> also<\/span> set<\/span> out <\/span>to<\/span> transition<\/span> adult<\/span> patients<\/span> in a <\/span>structured<\/span> manner<\/span> in <\/span>accordance<\/span> with<\/span> international<\/span> recommendations<\/span>, and <\/span>to<\/span> examine<\/span> the<\/span> usefulness<\/span> of <\/span>this<\/span> for<\/span> the<\/span> short<\/span>– and <\/span>long-term<\/span> outcome<\/span> of <\/span>the<\/span> disease<\/span>.<\/span> The <\/span>risk<\/span> of <\/span>s<\/span>clerosing<\/span> cholangitis<\/span> (SC) <\/span>is <\/span>elevated<\/span> in IBD. <\/span>One<\/span> of <\/span>the<\/span> new<\/span> directions<\/span> of <\/span>research<\/span> is <\/span>to<\/span> describe<\/span> the<\/span> natural<\/span> disease<\/span> course<\/span> of IBD <\/span>patients<\/span> with<\/span> SC, and <\/span>to<\/span> define<\/span> the<\/span> prognostic<\/span> markers.<\/span><\/span><\/p>\n

          We<\/span> are<\/span> also<\/span> investigating<\/span> the<\/span> role<\/span> of <\/span>eosinophil<\/span> granulocytes<\/span> in <\/span>inflammatory<\/span> bowel<\/span> disease<\/span>. <\/span>With<\/span> the<\/span> cooperation<\/span> of <\/span>the<\/span> Institute of <\/span>Pathology<\/span>, <\/span>Forensic<\/span> and <\/span>Insurance<\/span> Medicine<\/span>, <\/span>we<\/span> are<\/span> developing<\/span> an <\/span>artificial<\/span> intelligence-driven<\/span> program <\/span>to<\/span> determine<\/span> the<\/span> amount<\/span> of <\/span>eosinophil<\/span> granulocytes<\/span> in <\/span>intestinal<\/span> biopsies<\/span>. The <\/span>purpose<\/span> of <\/span>the<\/span> study<\/span> is <\/span>to<\/span> determine<\/span> whether<\/span> the<\/span> onset<\/span> of <\/span>the<\/span> disease<\/span> affects<\/span> the<\/span> amount<\/span> of <\/span>eosinophils<\/span>, <\/span>especially<\/span> in <\/span>early-onset<\/span> inflammatory<\/span> bowel<\/span> disease<\/span>, and <\/span>whether<\/span> there<\/span> is a <\/span>relationship<\/span> between<\/span> the<\/span> eosinophil<\/span> cell<\/span> count<\/span> and <\/span>the<\/span> prognosis<\/span> of <\/span>the<\/span> disease<\/span>.<\/span><\/p>\n

          In <\/span>addition<\/span> to<\/span> these<\/span>, <\/span>we<\/span> investigate<\/span> the<\/span> differences<\/span> of <\/span>the<\/span> gut-bound<\/span> mucosal<\/span> immune<\/span> system<\/span> in <\/span>immune-mediated<\/span> intestinal<\/span> diseases<\/span>. <\/span>Our<\/span> tests<\/span> focus<\/span> on<\/span> inflammatory<\/span> bowel<\/span> diseases<\/span>, <\/span>gluten<\/span> sensitivity<\/span> (<\/span>celiac<\/span> disease<\/span>) and <\/span>allergic<\/span> gastroenterological<\/span> symptoms<\/span>. In <\/span>these<\/span> pathologies<\/span>, <\/span>we<\/span> study<\/span> the<\/span> development<\/span> of <\/span>the<\/span> inflammatory<\/span> process<\/span>, <\/span>but<\/span> we<\/span> also<\/span> look<\/span> for<\/span> the<\/span> answer<\/span> to<\/span> how<\/span> the<\/span> scarring<\/span> (<\/span>fibrosis<\/span>) <\/span>that<\/span> causes<\/span> strictures<\/span> occurs<\/span> in <\/span>inflammatory<\/span> bowel<\/span> disease<\/span>. <\/span>We<\/span> also<\/span> look<\/span> for<\/span> the<\/span> clinical<\/span> and <\/span>laboratory<\/span> signs<\/span> that<\/span> help<\/span> in <\/span>the<\/span> more <\/span>accurate<\/span> diagnosis<\/span> of <\/span>these<\/span> pathologies<\/span>.<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"

          Munkacsoport vezet\u0151: Dr. Dezs\u0151fi-Gottl Antal, PhD, habilit\u00e1lt egyetemi docens Munkacsoport aktu\u00e1lis tagjai: Dr. Szab\u00f3 Dol\u00f3resz, PhD, egyetemi tan\u00e1rseg\u00e9d Dr. L\u00f3th Szendile, klinika szakorvos Dr. Perneczki Andrea, klinikai szakorvos Dr. Hazay Dorottya, klinikai szakorvos Hallgat\u00f3k: Dr. Erd\u00e9lyi-Percs \u00c9va, PhD hallgat\u00f3 Dr. Mohhamad Shagrani, PhD hallgat\u00f3 Balogh Andr\u00e1s, TDK hallgat\u00f3 Tam\u00e1s Marcell, TDK hallgat\u00f3 Guti Petra, TDK …<\/p>\n","protected":false},"author":101740,"featured_media":0,"parent":15,"menu_order":5,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"categories":[],"tags":[],"class_list":["post-193","page","type-page","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/semmelweis.hu\/bokayklinika\/wp-json\/wp\/v2\/pages\/193","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/semmelweis.hu\/bokayklinika\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/semmelweis.hu\/bokayklinika\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/semmelweis.hu\/bokayklinika\/wp-json\/wp\/v2\/users\/101740"}],"replies":[{"embeddable":true,"href":"https:\/\/semmelweis.hu\/bokayklinika\/wp-json\/wp\/v2\/comments?post=193"}],"version-history":[{"count":10,"href":"https:\/\/semmelweis.hu\/bokayklinika\/wp-json\/wp\/v2\/pages\/193\/revisions"}],"predecessor-version":[{"id":7110,"href":"https:\/\/semmelweis.hu\/bokayklinika\/wp-json\/wp\/v2\/pages\/193\/revisions\/7110"}],"up":[{"embeddable":true,"href":"https:\/\/semmelweis.hu\/bokayklinika\/wp-json\/wp\/v2\/pages\/15"}],"wp:attachment":[{"href":"https:\/\/semmelweis.hu\/bokayklinika\/wp-json\/wp\/v2\/media?parent=193"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/semmelweis.hu\/bokayklinika\/wp-json\/wp\/v2\/categories?post=193"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/semmelweis.hu\/bokayklinika\/wp-json\/wp\/v2\/tags?post=193"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}